KR20170132143A - 바이오마커 - Google Patents

바이오마커 Download PDF

Info

Publication number
KR20170132143A
KR20170132143A KR1020177024112A KR20177024112A KR20170132143A KR 20170132143 A KR20170132143 A KR 20170132143A KR 1020177024112 A KR1020177024112 A KR 1020177024112A KR 20177024112 A KR20177024112 A KR 20177024112A KR 20170132143 A KR20170132143 A KR 20170132143A
Authority
KR
South Korea
Prior art keywords
osm
osmr
ibd
individual
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177024112A
Other languages
English (en)
Korean (ko)
Inventor
나타니엘 리차드 웨스트
벤자민 마이클 조셉 오웬스
아메드 나빌 헤가지
피오나 마가렛 파우리
Original Assignee
옥스포드 유니버시티 이노베이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170132143(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1501480.6A external-priority patent/GB201501480D0/en
Priority claimed from GB201501511A external-priority patent/GB201501511D0/en
Priority claimed from GBGB1521446.3A external-priority patent/GB201521446D0/en
Application filed by 옥스포드 유니버시티 이노베이션 리미티드 filed Critical 옥스포드 유니버시티 이노베이션 리미티드
Publication of KR20170132143A publication Critical patent/KR20170132143A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177024112A 2015-01-29 2016-01-28 바이오마커 Withdrawn KR20170132143A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1501480.6A GB201501480D0 (en) 2015-01-29 2015-01-29 Biomarker
GB201501511A GB201501511D0 (en) 2015-01-29 2015-01-29 Biomarker
GB1501511.8 2015-01-29
GB1501480.6 2015-01-29
GBGB1521446.3A GB201521446D0 (en) 2015-12-04 2015-12-04 Biomarker
GB1521446.3 2015-12-04
PCT/GB2016/050185 WO2016120625A1 (en) 2015-01-29 2016-01-28 Biomarker

Publications (1)

Publication Number Publication Date
KR20170132143A true KR20170132143A (ko) 2017-12-01

Family

ID=55299667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024112A Withdrawn KR20170132143A (ko) 2015-01-29 2016-01-28 바이오마커

Country Status (8)

Country Link
US (1) US10822406B2 (enExample)
EP (2) EP3250599B1 (enExample)
JP (1) JP6999417B2 (enExample)
KR (1) KR20170132143A (enExample)
CN (1) CN107530431B (enExample)
AU (1) AU2016210996B2 (enExample)
MX (1) MX2017009695A (enExample)
WO (1) WO2016120625A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
JP2021522241A (ja) * 2018-04-25 2021-08-30 キニクサ ファーマシューティカルズ， リミテッド 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療
US11779643B2 (en) * 2019-08-28 2023-10-10 Children's Hospital Medical Center Methods and compositions for the treatment of an inflammatory bowel disease
JP7620324B2 (ja) * 2019-08-29 2025-01-23 国立大学法人東北大学 炎症性腸疾患の診断方法、診断プローブ及び診断キット
CN113699187B (zh) * 2020-05-20 2023-08-08 中国科学院微生物研究所 一种肠易激综合征小鼠模型及其应用
KR20230092978A (ko) 2020-10-19 2023-06-26 조에티스 서비시즈 엘엘씨 개 및 고양이 온코스타틴 m 수용체 베타에 대한 항체 및 이의 용도
IL285031A (en) * 2021-07-21 2023-02-01 Yeda Res & Dev Diagnosis of inflammatory bowel diseases
CN116377048B (zh) * 2022-04-22 2024-05-07 广州市妇女儿童医疗中心 S100a8/a9复合体在诊治先天性巨结肠中的应用
WO2025049876A1 (en) * 2023-09-01 2025-03-06 Genentech, Inc. Methods for treating inflammatory bowel disease
WO2025153079A1 (en) * 2024-01-19 2025-07-24 Biomap (Suzhou) Intelligent Technology Limited Method of treatment
CN119955922A (zh) * 2025-01-15 2025-05-09 浙江大学 生物标志物在制备炎症性肠病筛查或亚型检测产品的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693130B2 (en) 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6531506B1 (en) 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US5958442A (en) 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
WO2007143231A2 (en) * 2006-01-10 2007-12-13 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
EP1904050B1 (en) 2005-06-06 2012-11-14 The Regents of The University of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
US20080293582A1 (en) 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
WO2008028044A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
WO2010044952A2 (en) 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
CN103209731A (zh) 2010-09-30 2013-07-17 赢创有限公司 药物输送刀片及用于将药物储仓输送到目标部位的方法
PH12013500703A1 (en) 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
PL2643352T3 (pl) * 2010-11-23 2018-10-31 Glaxo Group Limited Białka wiążące antygen wiążące onkostatynę M (OSM)
WO2013168829A1 (en) 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
BR112015028338A2 (pt) 2013-05-17 2017-07-25 Genentech Inc métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
TR201815608T4 (tr) 2013-05-30 2018-11-21 Kiniksa Pharmaceuticals Ltd Onkastatin m reseptörü antijeni bağlayıcı proteinler.

Also Published As

Publication number Publication date
CN107530431B (zh) 2022-01-07
JP2018506528A (ja) 2018-03-08
EP3250599B1 (en) 2021-04-14
US20180022800A1 (en) 2018-01-25
AU2016210996A1 (en) 2017-08-17
WO2016120625A1 (en) 2016-08-04
US10822406B2 (en) 2020-11-03
CN107530431A (zh) 2018-01-02
JP6999417B2 (ja) 2022-02-04
MX2017009695A (es) 2018-04-10
AU2016210996B2 (en) 2021-08-12
EP3974450A2 (en) 2022-03-30
EP3250599A1 (en) 2017-12-06
EP3974450A3 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
CN107530431B (zh) 生物标志物
US20100322897A1 (en) Characterization of il-17f and il-17r interactions
KR20070092737A (ko) 임신 합병증의 진단 및 치료에 유용한 핵산 및 폴리펩티드
CN104244979A (zh) 使用il-17拮抗剂治疗强直性脊柱炎的方法
US20190094223A1 (en) Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
US20140037618A1 (en) Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
AU2021281359A1 (en) Markers and cellular antecedents of rheumatoid arthritis flares
JP2025169256A (ja) α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
WO2015157561A1 (en) Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
US20220291238A1 (en) Methods for Predicting Treatment Response in Ulcerative Colitis
WO2016002827A1 (ja) 進行型免疫性脱髄疾患治療剤
JP2010004750A (ja) 自己免疫疾患による組織傷害の発症または発症可能性の診断方法、およびその利用
CA3237899A1 (en) Markers and cellular antecedents of rheumatoid arthritis flares
US20250354998A1 (en) Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
Hong Act1-Mediated RNA Metabolism in IL-17-Driven Inflammatory Diseases
KR102282341B1 (ko) Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
KR102015527B1 (ko) 데스모글레인 3의 유전적 변이 및 이의 용도
US20220298580A1 (en) Immune signatures predictive of response to pd-1 blockade in richter's transformation
CN119343148A (zh) 使用angptl4拮抗剂治疗肝纤维化、炎症或相关疾病的方法
WO2025264878A1 (en) Methods and compositions for modulating stem-like t cells in autoimmune disease
Nistala et al. Th17 cells that undergo plasticity to a Th1 phenotype in human autoimmune arthritis can be detected by the expression of CD161 within the inflamed joint
Smith The Role of CXCL10 in the Pathogenesis of Rheumatoid Arthritis Joint Damage

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170828

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination